| Code | CSB-RA011662MB5HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to SHR-1703, targeting interleukin-5 (IL5), a key cytokine in eosinophil biology. IL5 plays a central role in the differentiation, maturation, activation, and survival of eosinophils, making it a critical mediator in allergic inflammation and eosinophilic disorders. Elevated IL5 levels are associated with various conditions including asthma, chronic obstructive pulmonary disease, eosinophilic esophagitis, hypereosinophilic syndrome, and certain parasitic infections. By binding to IL5, this antibody can neutralize its biological activity and prevent interaction with the IL5 receptor on eosinophils.
SHR-1703 represents a therapeutic antibody designed to target IL5-mediated pathways in eosinophilic diseases. This biosimilar provides researchers with a valuable tool for investigating IL5 signaling mechanisms, eosinophil-dependent immune responses, and potential therapeutic interventions in allergic and inflammatory conditions. It supports studies exploring the pathophysiology of eosinophilic disorders and enables evaluation of IL5 blockade strategies in various experimental models.
There are currently no reviews for this product.